Sean O'Sullivan
Managing General Partner and Founder @ SOSV
Princeton, United States
Sean O'Sullivan is a convertible note investor at SOSV in Princeton focused on Biotechnology and Health Care. Sean O’Sullivan is the Founder and Managing General Partner of SOSV. He previously worked at Mapflow as a Chairman. Sean O’Sullivan attended Rensselaer Polytechnic Institute.
- Total investments:
- 74
- Last investment:
- Lead investor:
- 16%
Last updated:
For AI agents: llms.txt
Industries Sean O'Sullivan invests in
Stages Sean O'Sullivan invests in
Countries Sean O'Sullivan invests in
Round sizes
Round size
- Seed
- $31k–$3.3M
- Pre-Seed
- $250k–$1.5M
Investment Focus
Industry
- Biotechnology 13 (18%)
- Health Care 7 (9%)
- Health Diagnostics 4 (5%)
- Car Sharing 3 (4%)
- Transportation 3 (4%)
Stage
- Convertible Note 10 (14%)
- Seed 9 (12%)
- Pre-Seed 3 (4%)
- Funding Round 3 (4%)
- Series A 2 (3%)
Country
- United States 18 (24%)
- Ireland 2 (3%)
- India 1 (1%)
- Spain 1 (1%)
- France 1 (1%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
VALANX Biotech
|
VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development. | $3.5M / Venture - Series Unknown / Mar 12, 2026 | |
Prellis Biologics
|
Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics' technology leverages massive gains in print speed and resolution to break the microvasculature barrier.The companywas founded in 2016 and is based in San Francisco, California. | Series C / Nov 07, 2025 | |
Flore by Sun Genomics
|
Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completelypersonalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes. | Convertible Note / Aug 15, 2025 | |
|
Prellis Biologics
|
Prellis Biologics is building human tissues for drug development, and ultimately, developing human organs for transplantation. Bioprinting vascularized human tissue and organs will revolutionize healthcare. Prellis Biologics' technology leverages massive gains in print speed and resolution to break the microvasculature barrier.The companywas founded in 2016 and is based in San Francisco, California. | Series C / Mar 10, 2025 | |
|
Flore by Sun Genomics
|
Sun Genomics is a precision nutrition company focused on curing dysbiosis through the gut microflora and personalized solutions. Its flagship product Floré, is a microbiome test and custom synbiotics solution that utilizes whole-genome sequencing to evaluate different digestive system data points and ensure that customers receive a completelypersonalized product based on their unique gut profiles. The company also offers: Floré Tots, Kids, and Baby, available for kids up to age 0-12, and comes in an easy digestive powder to mix with their favorite drink. Floré Clinical, which is specifically for professional practitioners and their patients. Floré Defense, Balance, and Performance for sports teams and athletes. | Convertible Note / Nov 19, 2024 | |
MixRift
|
MixRift is a gaming company that specializes in designing and developing interactive and mixed-reality gaming experiences. | $1.5M / Pre-Seed / Aug 07, 2024 | |
|
VALANX Biotech
|
VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development. | Seed / Jul 16, 2024 | |
GlowDx
|
GlowDx is decentralising molecular testing through point-of-care testing using a novel molecular technology. This enables local access, reducing both the economic and disease burden of patients. | Convertible Note / Jun 18, 2024 | |
|
MixRift
|
MixRift is a gaming company that specializes in designing and developing interactive and mixed-reality gaming experiences. | Pre-Seed / May 02, 2024 | |
Cell BioEngines
|
Cell BioEngines, Inc., is a clinical-stage biotech company focused on curing cancer by developing ”off-the-shelf” allogenic cell therapies. The company leverages its proprietary Stem-SPACE platform technology to produce clinical grade cells at scale. | $500K / Pre-Seed / Apr 23, 2024 | |
| See all 74 investments → | |||
Co-Investors
About SOSV
SOSV is a global venture capital firm that focuses on deep tech investments through the HAX and IndieBio startup development programs aimed at human and planetary health. The firm invests in startups at their inception, providing support to accelerate their next institutional funding round. HAX offers facilities and engineering resources, whileIndieBio provides services and lab equipment for founders. The firm targets deep technology innovations in the health and environmental sectors.
SOSV Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Arvind Gupta
General Partner
|
|||
Blaine Doyle
Mentor
|
|||
Cyril Ebersweiler
General Partner
|
|||
Deborah Zajac
General Partner
|
|||
Duncan Turner
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Sean O'Sullivan invest in?
Sean O'Sullivan invests primarily in Biotechnology, Health Care and Health Diagnostics startups, most often at Convertible Note and Seed stage. Most of the 74 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Sean O'Sullivan's check size?
Sean O'Sullivan typically joins rounds of $31k–$3.3M at Seed and $250k–$1.5M at Pre-Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sean O'Sullivan participates in.
When did Sean O'Sullivan last invest?
The most recent investment recorded for Sean O'Sullivan closed in Mar 2026. Shizune tracks 74 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
